The authors reported the success of IL-17 neutralization to prevent short-term memory impairment and hippocampal glutamatergic dysfunction in early AD stages while prolonged anti-IL-17 infusion delayed cognitive impairment, and reduced peripheral inflammation in later AD stages. The gene discussed is IL17A; the disease is memory impairment.